Novel spatial, temporal, and energetically resolved measurements of bremsstrahlung hard-x-ray (HXR) emission from runaway electron (RE) populations in tokamaks reveal nonmonotonic RE distribution ...functions whose properties depend on the interplay of electric field acceleration with collisional and synchrotron damping. Measurements are consistent with theoretical predictions of momentum-space attractors that accumulate runaway electrons. RE distribution functions are measured to shift to a higher energy when the synchrotron force is reduced by decreasing the toroidal magnetic field strength. Increasing the collisional damping by increasing the electron density (at a fixed magnetic and electric field) reduces the energy of the nonmonotonic feature and reduces the HXR growth rate at all energies. Higher-energy HXR growth rates extrapolate to zero at the expected threshold electric field for RE sustainment, while low-energy REs are anomalously lost. The compilation of HXR emission from different sight lines into the plasma yields energy and pitch-angle-resolved RE distributions and demonstrates increasing pitch-angle and radial gradients with energy.
Experiments in the DIII-D tokamak show that fast-ion transport suddenly becomes stiff above a critical threshold in the presence of many overlapping small-amplitude Alfvén eigenmodes (AEs). The ...threshold is phase-space dependent and occurs when particle orbits become stochastic due to resonances with AEs. Above threshold, equilibrium fast-ion density profiles are unchanged despite increased drive, and intermittent fast-ion losses are observed. Fast-ion Dα spectroscopy indicates radially localized transport of the copassing population at radii that correspond to the location of midcore AEs. The observation of stiff fast-ion transport suggests that reduced models can be used to effectively predict alpha profiles, beam ion profiles, and losses to aid in the design of optimized scenarios for future burning plasma devices.
GOALS:We studied the prevalence and predictors of small-intestinal bacterial overgrowth (SIBO) in Crohn’s disease (CD) outpatients and the relationship between SIBO and intestinal and/or systemic ...inflammation.
BACKGROUND:The relationship of SIBO with systemic and intestinal inflammation in CD patients is unclear.
STUDY:In this cross-sectional study, conducted between June, 2013 and January, 2015, 92 CD patients and 97 controls with nonchronic gastrointestinal complaints were assessed for the presence of SIBO using the H2/CH4 glucose breath test. Multivariate logistic regression was performed to investigate the potential association between SIBO and demographic, disease-related data, systemic markers of inflammation (C-reactive protein, and erythrocyte sedimentation rate), and biomarker of intestinal inflammation fecal calprotectin concentration (FCC).
RESULTS:The SIBO rate was significantly higher in CD patients than in controls (32.6% vs. 12.4%, respectively, P=0.0008). Patients with and without SIBO were comparable with regard to demographics, systemic inflammatory biomarkers, and disease characteristics, except for the stricturing phenotype being more common in SIBO-positive CD patients (43.3% vs. 19.3%, P=0.015). Notably, FCC was significantly higher in SIBO-positive patients (median of 485.8 vs.132.7 μg/g; P=0.004). Patients presenting increased FCC and stricturing disease had an odds of 9.43 (95% confidence interval, 3.04-11.31; P<0.0001) and 3.83 (95% confidence interval, 1.54-6.75; P=0.025) respectively, for SIBO diagnosis.
CONCLUSIONS:In CD patients, SIBO is a highly prevalent condition. Stricturing phenotype and increased FCC were strongly and independently associated with the presence of SIBO. SIBO diagnostic work-up followed by directed treatment is recommended in CD patients who present stricturing disease, especially in those with concurrent intestinal inflammation.
THE MATERHORN Fernando, H. J. S.; Pardyjak, E. R.; Di Sabatino, S. ...
Bulletin of the American Meteorological Society,
11/2015, Letnik:
96, Številka:
11
Journal Article
Recenzirano
Odprti dostop
Emerging application areas such as air pollution in megacities, wind energy, urban security, and operation of unmanned aerial vehicles have intensified scientific and societal interest in mountain ...meteorology. To address scientific needs and help improve the prediction of mountain weather, the U.S. Department of Defense has funded a research effort—the Mountain Terrain Atmospheric Modeling and Observations (MATERHORN) Program—that draws the expertise of a multidisciplinary, multiinstitutional, and multinational group of researchers. The program has four principal thrusts, encompassing modeling, experimental, technology, and parameterization components, directed at diagnosing model deficiencies and critical knowledge gaps, conducting experimental studies, and developing tools for model improvements. The access to the Granite Mountain Atmospheric Sciences Testbed of the U.S. Army Dugway Proving Ground, as well as to a suite of conventional and novel high-end airborne and surface measurement platforms, has provided an unprecedented opportunity to investigate phenomena of time scales from a few seconds to a few days, covering spatial extents of tens of kilometers down to millimeters. This article provides an overview of the MATERHORN and a glimpse at its initial findings. Orographic forcing creates a multitude of time-dependent submesoscale phenomena that contribute to the variability of mountain weather at mesoscale. The nexus of predictions by mesoscale model ensembles and observations are described, identifying opportunities for further improvements in mountain weather forecasting.
Celotno besedilo
Dostopno za:
BFBNIB, DOBA, IZUM, KILJ, NUK, PILJ, PNG, SAZU, SIK, UILJ, UKNU, UL, UM, UPUK
Several tyrosine kinase inhibitors have activity in Ph-positive chronic and acute leukemia, but resistant disease and unacceptable side effects may limit efficacy. Ponatinib showed a high level of ...activity in a phase 2 study of tyrosine kinase inhibitor–resistant disease but was associated with arterial thrombosis.
Patients with newly diagnosed chronic myeloid leukemia (CML) frequently receive imatinib. Although initial response rates are high, imatinib fails in up to 40% of patients because of disease resistance, frequently because of BCR-ABL kinase domain mutations or unacceptable side effects.
1
,
2
Patients who discontinue imatinib may have a response to second-generation tyrosine kinase inhibitors. However, 37 to 52% of patients do not have a response,
3
–
8
and 23 to 26% of patients have an initial major cytogenetic response that is lost by 2 years.
3
,
9
The prognosis for these patients is very poor. With the exception of the small number . . .
PDF
